科美诊断(688468) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥118,535,231.69, a decrease of 17.84% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥37,787,512.59, down 16.82% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,603,067.90, a decrease of 29.89% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 reached ¥355,463,272.78, an increase from ¥295,657,726.42 in the same period of 2020, representing a growth of approximately 20.2%[22] - Total operating costs for the first three quarters of 2021 were ¥244,220,961.08, compared to ¥218,506,898.71 in the same period of 2020, reflecting an increase of about 11.8%[23] - Operating profit for the first three quarters of 2021 was ¥123,442,779.63, up from ¥90,075,919.16 in the same period of 2020, indicating a growth of approximately 37.0%[23] - The net profit for Q3 2021 was CNY 107,803,052.25, an increase of 40.8% compared to CNY 76,595,066.44 in Q3 2020[24] - The total comprehensive income for Q3 2021 was CNY 107,803,052.25, reflecting a 40.8% increase from CNY 76,595,066.44 in Q3 2020[25] Cash Flow and Liquidity - The cash flow generated from operating activities for the year-to-date was ¥149,520,066.42, an increase of 55.75% compared to the previous year[6] - The company's cash and cash equivalents as of September 30, 2021, were ¥176,210,193.04, down from ¥224,817,311.69 at the end of 2020, a decrease of about 21.5%[18] - Cash flow from operating activities for the first three quarters of 2021 was CNY 149,520,066.42, compared to CNY 96,001,816.24 in the previous year, indicating a growth of 55.7%[28] - The company reported a total operating cash inflow of CNY 415,628,012.48 for the first three quarters of 2021, compared to CNY 328,543,128.29 in the same period last year, marking a 26.5% increase[27] - The total operating cash outflow for the first three quarters of 2021 was CNY 266,107,946.06, compared to CNY 232,541,312.05 in the previous year, an increase of 14.4%[28] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,400,482,989.61, reflecting a 39.10% increase from the end of the previous year[6] - The company's total assets as of September 30, 2021, amounted to ¥1,400,482,989.61, compared to ¥1,006,822,552.60 at the end of 2020, representing an increase of approximately 38.9%[20] - The company's total liabilities as of September 30, 2021, were ¥156,764,434.06, up from ¥119,463,997.34 at the end of 2020, reflecting an increase of about 31.2%[20] - Total liabilities were $119,463,997.34, reflecting a decrease of $10,199,341.75 from the previous period[32] - The total current assets and liabilities indicate a stable liquidity position for the company[31][32] Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 8,218[12] - The largest shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management Partnership, holds 26.6% of shares, totaling 108,000,000 shares[12] - The second-largest shareholder, Shanghai Peixi Investment Management Partnership, holds 11.3% of shares, totaling 45,421,070 shares[12] - The company has a total of 22,710,530 shares held by Shenzhen Ping An Real Estate Investment Co., accounting for 5.6% of shares[12] - The report indicates that the top ten shareholders have significant interconnected relationships, with the actual controller holding substantial stakes in multiple entities[13] Research and Development - Research and development expenses totaled ¥16,759,354.04 for the quarter, a decrease of 19.99% compared to the same period last year[6] - The company has invested significantly in R&D, with R&D expenses for the first three quarters of 2021 totaling ¥48,243,992.75, compared to ¥43,641,529.46 in the same period of 2020, an increase of approximately 10.5%[23] - The company plans to continue its active investment in R&D and patent layout, focusing on various clinical applications[16] - The report highlights a significant academic paper validating the performance of the LICA® technology for progesterone quantification, emphasizing its high sensitivity and accuracy[15] - The company is focusing on expanding its product offerings in the field of hormone detection, particularly with the LICA® technology[15] - The company obtained 4 domestic Class II medical device registration certificates during the reporting period, with 17 products in the review stage and 9 in clinical trials, covering common clinical areas such as infectious diseases and tumors[16] - The company received 6 authorized patents during the reporting period, including 1 domestic invention patent and 4 design patents[17] Market Strategy - The company is exploring potential market expansion strategies to increase its footprint in the diagnostics sector[15] - The company completed its initial public offering, which contributed to the increase in total assets and equity[10] - The company is committed to enhancing its research capabilities and product development in response to market demands[15]